Being a lab rat for phase I trials for extended-release versions of drugs that are already well-known - a potential windfall financial opportunity for rationalists?
This is one of the cases where better information (which we can easily get as rationalists) can really pay off. I got paid over $500 to test Concerta, which is basically the extended-release version of Ritalin (and it was one of the last stages too, even after it got FDA-approved). And Ritalin's effects are already very well-known.
Many people are systematically prone to overestimating the risks from drugs (due to an intrinsic resistance to anything "unnatural"), especially since they don't do any research into them. Now, certainly, there is *some* chance that Phase I drugs could end up as disasters - http://en.wikipedia.org/wiki/TGN1412 foremost among them. And there's also a chance that you could end up with http://en.wikipedia.org/wiki/Rosiglitazone (but then, if you're only taking it for a few weeks, there probably won't be any permanent damage).
But these are still the exceptions rather than the norm, and you're still probably more likely to die from a car accident. Furthermore, these types of things aren't going to happen to extended release forms (and the FDA still somehow requires stringent testing for new extended release forms of drugs). Some of us rationalists excel at doing research, and can easily estimate the risks of most drugs (and go straight into the journal papers to see relative ratios and LD50s [and the dose required to cause severe side effects in any human, which is usually much higher than the normal dose]). Furthermore, in the new era of genomic sequencing, we may even be able to better predict how our body will respond to these drugs (for example, we can see which receptors we're over-sensitive too, and which ones we're not so oversensitive to, as well as our expression of Cytochrome p450 enzymes). So maybe this is a potential windfall for some of us?
Especially in the future, since we're in the age where we are rapidly learning about biological networks?
Even then, it doesn't have to be Phase I.
With that all being said, it's probably wise to avoid getting too many blood draws from the same vein